Loading…
Activation of Toll‐like receptor 7 provides cardioprotection in septic cardiomyopathy‐induced systolic dysfunction
ABSTRACT Background As a pattern recognition receptor, Toll‐like receptor 7 (TLR7) widely presented in the endosomal membrane of various cells. However, the precise role and mechanism of TLR7 in septic cardiomyopathy remain unknown. This study aims to determine the role of TLR7 in cardiac dysfunctio...
Saved in:
Published in: | Clinical and translational medicine 2021-01, Vol.11 (1), p.e266-n/a |
---|---|
Main Authors: | , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c4356-7580adf072c996c24ad787daa9f4910a6b10bf4de79bb857913941dc504df4f43 |
---|---|
cites | cdi_FETCH-LOGICAL-c4356-7580adf072c996c24ad787daa9f4910a6b10bf4de79bb857913941dc504df4f43 |
container_end_page | n/a |
container_issue | 1 |
container_start_page | e266 |
container_title | Clinical and translational medicine |
container_volume | 11 |
creator | Saiyang, Xie Qingqing, Wu man, Xu Chen, Liu Min, Zhang Yun, Xing Wenke, Shi Haiming, Wu Xiaofeng, Zeng Si, Chen Haipeng, Guo Wei, Deng Qizhu, Tang |
description | ABSTRACT
Background
As a pattern recognition receptor, Toll‐like receptor 7 (TLR7) widely presented in the endosomal membrane of various cells. However, the precise role and mechanism of TLR7 in septic cardiomyopathy remain unknown. This study aims to determine the role of TLR7 in cardiac dysfunction during sepsis and explore the mechanism of TLR7 in septic cardiomyopathy.
Methods
We generated a mouse model of septic cardiomyopathy by challenging with lipopolysaccharide (LPS). TLR7‐knockout (TLR7−/−), wild‐type (WT) mice, cardiac‐specific TLR7‐transgenic (cTG‐TLR7) overexpression, and littermates WT (LWT) mice were subjected to septic model. Additionally, to verify the role and mechanism of TLR7 in vitro, we transfected neonatal rat ventricular myocytes (NRVMs) with Ad‐TLR7 and TLR7 siRNA before LPS administration. The effects of TLR7 were assessed by Ca2+ imaging, western blotting, immunostaining, and quantitative real‐time polymerase chain reaction (qPCR).
Results
We found that TLR7 knockout markedly exacerbated sepsis‐induced systolic dysfunction. Moreover, cardiomyocytes isolated from TLR7−/− mice displayed weaker Ca2+ handling than that in WT mice in response to LPS. Conversely, TLR7 overexpression alleviated LPS‐induced systolic dysfunction, and loxoribine (TLR7‐specific agonist) improved LPS‐induced cardiac dysfunction. Mechanistically, these optimized effects were associated with enhanced the adenosine (cAMP)‐protein kinase A (PKA) pathway, which upregulated phosphorylate‐phospholamban (p‐PLN) (Ser16) and promoted sarco/endoplasmic reticulum Ca2+ ATPase (Serca) and Ryanodine Receptor 2 (RyR2) expression in the sarcoplasmic reticulum (SR), and ultimately restored Ca2+ handling in response to sepsis. While improved Ca2+ handling was abrogated after H89 (a specific PKA inhibitor) pretreatment in cardiomyocytes isolated from cTG‐TLR7 mice. Consistently, TLR7 overexpression improved LPS‐induced Ca2+‐handling decrement in NRVMs. Nevertheless, TLR7 knockdown showed a deteriorative phenotype.
Conclusions
Our data demonstrated that activation of TLR7 protected against sepsis‐induced cardiac dysfunction through promoting cAMP‐PKA‐PLN pathway, and we revealed that TLR7 might be a novel therapeutic target to block the septic cardiomyopathy and support systolic function during sepsis.
Our study explored the effect of TLR7 activation, by which TLR7 modulated Ca2+ handling in septic cardiomyopathy. TLR7 protected against sepsis‐induced cardiac dysfunction through |
doi_str_mv | 10.1002/ctm2.266 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7775988</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2479042327</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4356-7580adf072c996c24ad787daa9f4910a6b10bf4de79bb857913941dc504df4f43</originalsourceid><addsrcrecordid>eNp1kc1KHTEYhkNpqWKFXkEZcNPN2CSTSSYbQQ6tCpZuTtchk58am5mMSeaU2fUSvEavxBw9tVpoFvnhe76HL7wAvEfwGEGIP6k84GNM6SuwjyFENWowff3svgcOU7qGZXWEc4bfgr2mIbSBFO2DzanKbiOzC2MVbLUO3t_9vvXup6miUWbKIVasmmLYOG1SpWTULpRnNuqhx41VKpRTu9KwhEnmq6VI3KhnZXSVlpSDL4Rekp3Hh7534I2VPpnD3XkAvn_5vF6d15ffzi5Wp5e1Ik1La9Z2UGoLGVacU4WJ1KxjWkpuCUdQ0h7B3hJtGO_7rmUcNZwgrVpItCWWNAfg5NE7zf1gtDJjjtKLKbpBxkUE6cTLyuiuxI-wEYyxlnddEXzcCWK4mU3KYnBJGe_laMKcBCaMQ4IbzAp69A96HeY4lu8JzCiGaLv9FaoYUorGPg2DoNjmKbZ5ipJnQT88H_4J_JNeAepH4JfzZvmvSKzWX_FWeA8VVq5f</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2762017620</pqid></control><display><type>article</type><title>Activation of Toll‐like receptor 7 provides cardioprotection in septic cardiomyopathy‐induced systolic dysfunction</title><source>Open Access: PubMed Central</source><source>Open Access: Wiley-Blackwell Open Access Journals</source><source>Publicly Available Content (ProQuest)</source><creator>Saiyang, Xie ; Qingqing, Wu ; man, Xu ; Chen, Liu ; Min, Zhang ; Yun, Xing ; Wenke, Shi ; Haiming, Wu ; Xiaofeng, Zeng ; Si, Chen ; Haipeng, Guo ; Wei, Deng ; Qizhu, Tang</creator><creatorcontrib>Saiyang, Xie ; Qingqing, Wu ; man, Xu ; Chen, Liu ; Min, Zhang ; Yun, Xing ; Wenke, Shi ; Haiming, Wu ; Xiaofeng, Zeng ; Si, Chen ; Haipeng, Guo ; Wei, Deng ; Qizhu, Tang</creatorcontrib><description>ABSTRACT
Background
As a pattern recognition receptor, Toll‐like receptor 7 (TLR7) widely presented in the endosomal membrane of various cells. However, the precise role and mechanism of TLR7 in septic cardiomyopathy remain unknown. This study aims to determine the role of TLR7 in cardiac dysfunction during sepsis and explore the mechanism of TLR7 in septic cardiomyopathy.
Methods
We generated a mouse model of septic cardiomyopathy by challenging with lipopolysaccharide (LPS). TLR7‐knockout (TLR7−/−), wild‐type (WT) mice, cardiac‐specific TLR7‐transgenic (cTG‐TLR7) overexpression, and littermates WT (LWT) mice were subjected to septic model. Additionally, to verify the role and mechanism of TLR7 in vitro, we transfected neonatal rat ventricular myocytes (NRVMs) with Ad‐TLR7 and TLR7 siRNA before LPS administration. The effects of TLR7 were assessed by Ca2+ imaging, western blotting, immunostaining, and quantitative real‐time polymerase chain reaction (qPCR).
Results
We found that TLR7 knockout markedly exacerbated sepsis‐induced systolic dysfunction. Moreover, cardiomyocytes isolated from TLR7−/− mice displayed weaker Ca2+ handling than that in WT mice in response to LPS. Conversely, TLR7 overexpression alleviated LPS‐induced systolic dysfunction, and loxoribine (TLR7‐specific agonist) improved LPS‐induced cardiac dysfunction. Mechanistically, these optimized effects were associated with enhanced the adenosine (cAMP)‐protein kinase A (PKA) pathway, which upregulated phosphorylate‐phospholamban (p‐PLN) (Ser16) and promoted sarco/endoplasmic reticulum Ca2+ ATPase (Serca) and Ryanodine Receptor 2 (RyR2) expression in the sarcoplasmic reticulum (SR), and ultimately restored Ca2+ handling in response to sepsis. While improved Ca2+ handling was abrogated after H89 (a specific PKA inhibitor) pretreatment in cardiomyocytes isolated from cTG‐TLR7 mice. Consistently, TLR7 overexpression improved LPS‐induced Ca2+‐handling decrement in NRVMs. Nevertheless, TLR7 knockdown showed a deteriorative phenotype.
Conclusions
Our data demonstrated that activation of TLR7 protected against sepsis‐induced cardiac dysfunction through promoting cAMP‐PKA‐PLN pathway, and we revealed that TLR7 might be a novel therapeutic target to block the septic cardiomyopathy and support systolic function during sepsis.
Our study explored the effect of TLR7 activation, by which TLR7 modulated Ca2+ handling in septic cardiomyopathy. TLR7 protected against sepsis‐induced cardiac dysfunction through activation of cAMP‐PKA‐PLN pathway. Targeting this newly identified TLR7 may yield novel interventional solutions against septic cardiomyopathy.</description><identifier>ISSN: 2001-1326</identifier><identifier>EISSN: 2001-1326</identifier><identifier>DOI: 10.1002/ctm2.266</identifier><identifier>PMID: 33463061</identifier><language>eng</language><publisher>United States: John Wiley & Sons, Inc</publisher><subject>Animals ; Antibodies ; Ca2+‐handling ; cardiac dysfunction ; Cardiomyocytes ; Cardiomyopathies - complications ; Cardiomyopathies - prevention & control ; Cardiomyopathy ; Clinical medicine ; Cybernetics ; Disease Models, Animal ; Ejection fraction ; Endoplasmic reticulum ; Heart ; Hemodynamics ; Homeostasis ; Kinases ; Laboratory animals ; Male ; Membrane Glycoproteins - pharmacology ; Mice ; Mice, Inbred C57BL ; Proteins ; Sepsis ; Sepsis - complications ; septic cardiomyopathy ; Systole ; TLR7 ; Toll-Like Receptor 7</subject><ispartof>Clinical and translational medicine, 2021-01, Vol.11 (1), p.e266-n/a</ispartof><rights>2020 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics</rights><rights>2020 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.</rights><rights>2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4356-7580adf072c996c24ad787daa9f4910a6b10bf4de79bb857913941dc504df4f43</citedby><cites>FETCH-LOGICAL-c4356-7580adf072c996c24ad787daa9f4910a6b10bf4de79bb857913941dc504df4f43</cites><orcidid>0000-0003-4883-4226 ; 0000-0003-2210-3169</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2762017620/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2762017620?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,11562,25753,27924,27925,37012,37013,44590,46052,46476,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33463061$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Saiyang, Xie</creatorcontrib><creatorcontrib>Qingqing, Wu</creatorcontrib><creatorcontrib>man, Xu</creatorcontrib><creatorcontrib>Chen, Liu</creatorcontrib><creatorcontrib>Min, Zhang</creatorcontrib><creatorcontrib>Yun, Xing</creatorcontrib><creatorcontrib>Wenke, Shi</creatorcontrib><creatorcontrib>Haiming, Wu</creatorcontrib><creatorcontrib>Xiaofeng, Zeng</creatorcontrib><creatorcontrib>Si, Chen</creatorcontrib><creatorcontrib>Haipeng, Guo</creatorcontrib><creatorcontrib>Wei, Deng</creatorcontrib><creatorcontrib>Qizhu, Tang</creatorcontrib><title>Activation of Toll‐like receptor 7 provides cardioprotection in septic cardiomyopathy‐induced systolic dysfunction</title><title>Clinical and translational medicine</title><addtitle>Clin Transl Med</addtitle><description>ABSTRACT
Background
As a pattern recognition receptor, Toll‐like receptor 7 (TLR7) widely presented in the endosomal membrane of various cells. However, the precise role and mechanism of TLR7 in septic cardiomyopathy remain unknown. This study aims to determine the role of TLR7 in cardiac dysfunction during sepsis and explore the mechanism of TLR7 in septic cardiomyopathy.
Methods
We generated a mouse model of septic cardiomyopathy by challenging with lipopolysaccharide (LPS). TLR7‐knockout (TLR7−/−), wild‐type (WT) mice, cardiac‐specific TLR7‐transgenic (cTG‐TLR7) overexpression, and littermates WT (LWT) mice were subjected to septic model. Additionally, to verify the role and mechanism of TLR7 in vitro, we transfected neonatal rat ventricular myocytes (NRVMs) with Ad‐TLR7 and TLR7 siRNA before LPS administration. The effects of TLR7 were assessed by Ca2+ imaging, western blotting, immunostaining, and quantitative real‐time polymerase chain reaction (qPCR).
Results
We found that TLR7 knockout markedly exacerbated sepsis‐induced systolic dysfunction. Moreover, cardiomyocytes isolated from TLR7−/− mice displayed weaker Ca2+ handling than that in WT mice in response to LPS. Conversely, TLR7 overexpression alleviated LPS‐induced systolic dysfunction, and loxoribine (TLR7‐specific agonist) improved LPS‐induced cardiac dysfunction. Mechanistically, these optimized effects were associated with enhanced the adenosine (cAMP)‐protein kinase A (PKA) pathway, which upregulated phosphorylate‐phospholamban (p‐PLN) (Ser16) and promoted sarco/endoplasmic reticulum Ca2+ ATPase (Serca) and Ryanodine Receptor 2 (RyR2) expression in the sarcoplasmic reticulum (SR), and ultimately restored Ca2+ handling in response to sepsis. While improved Ca2+ handling was abrogated after H89 (a specific PKA inhibitor) pretreatment in cardiomyocytes isolated from cTG‐TLR7 mice. Consistently, TLR7 overexpression improved LPS‐induced Ca2+‐handling decrement in NRVMs. Nevertheless, TLR7 knockdown showed a deteriorative phenotype.
Conclusions
Our data demonstrated that activation of TLR7 protected against sepsis‐induced cardiac dysfunction through promoting cAMP‐PKA‐PLN pathway, and we revealed that TLR7 might be a novel therapeutic target to block the septic cardiomyopathy and support systolic function during sepsis.
Our study explored the effect of TLR7 activation, by which TLR7 modulated Ca2+ handling in septic cardiomyopathy. TLR7 protected against sepsis‐induced cardiac dysfunction through activation of cAMP‐PKA‐PLN pathway. Targeting this newly identified TLR7 may yield novel interventional solutions against septic cardiomyopathy.</description><subject>Animals</subject><subject>Antibodies</subject><subject>Ca2+‐handling</subject><subject>cardiac dysfunction</subject><subject>Cardiomyocytes</subject><subject>Cardiomyopathies - complications</subject><subject>Cardiomyopathies - prevention & control</subject><subject>Cardiomyopathy</subject><subject>Clinical medicine</subject><subject>Cybernetics</subject><subject>Disease Models, Animal</subject><subject>Ejection fraction</subject><subject>Endoplasmic reticulum</subject><subject>Heart</subject><subject>Hemodynamics</subject><subject>Homeostasis</subject><subject>Kinases</subject><subject>Laboratory animals</subject><subject>Male</subject><subject>Membrane Glycoproteins - pharmacology</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Proteins</subject><subject>Sepsis</subject><subject>Sepsis - complications</subject><subject>septic cardiomyopathy</subject><subject>Systole</subject><subject>TLR7</subject><subject>Toll-Like Receptor 7</subject><issn>2001-1326</issn><issn>2001-1326</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>PIMPY</sourceid><recordid>eNp1kc1KHTEYhkNpqWKFXkEZcNPN2CSTSSYbQQ6tCpZuTtchk58am5mMSeaU2fUSvEavxBw9tVpoFvnhe76HL7wAvEfwGEGIP6k84GNM6SuwjyFENWowff3svgcOU7qGZXWEc4bfgr2mIbSBFO2DzanKbiOzC2MVbLUO3t_9vvXup6miUWbKIVasmmLYOG1SpWTULpRnNuqhx41VKpRTu9KwhEnmq6VI3KhnZXSVlpSDL4Rekp3Hh7534I2VPpnD3XkAvn_5vF6d15ffzi5Wp5e1Ik1La9Z2UGoLGVacU4WJ1KxjWkpuCUdQ0h7B3hJtGO_7rmUcNZwgrVpItCWWNAfg5NE7zf1gtDJjjtKLKbpBxkUE6cTLyuiuxI-wEYyxlnddEXzcCWK4mU3KYnBJGe_laMKcBCaMQ4IbzAp69A96HeY4lu8JzCiGaLv9FaoYUorGPg2DoNjmKbZ5ipJnQT88H_4J_JNeAepH4JfzZvmvSKzWX_FWeA8VVq5f</recordid><startdate>202101</startdate><enddate>202101</enddate><creator>Saiyang, Xie</creator><creator>Qingqing, Wu</creator><creator>man, Xu</creator><creator>Chen, Liu</creator><creator>Min, Zhang</creator><creator>Yun, Xing</creator><creator>Wenke, Shi</creator><creator>Haiming, Wu</creator><creator>Xiaofeng, Zeng</creator><creator>Si, Chen</creator><creator>Haipeng, Guo</creator><creator>Wei, Deng</creator><creator>Qizhu, Tang</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4883-4226</orcidid><orcidid>https://orcid.org/0000-0003-2210-3169</orcidid></search><sort><creationdate>202101</creationdate><title>Activation of Toll‐like receptor 7 provides cardioprotection in septic cardiomyopathy‐induced systolic dysfunction</title><author>Saiyang, Xie ; Qingqing, Wu ; man, Xu ; Chen, Liu ; Min, Zhang ; Yun, Xing ; Wenke, Shi ; Haiming, Wu ; Xiaofeng, Zeng ; Si, Chen ; Haipeng, Guo ; Wei, Deng ; Qizhu, Tang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4356-7580adf072c996c24ad787daa9f4910a6b10bf4de79bb857913941dc504df4f43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Animals</topic><topic>Antibodies</topic><topic>Ca2+‐handling</topic><topic>cardiac dysfunction</topic><topic>Cardiomyocytes</topic><topic>Cardiomyopathies - complications</topic><topic>Cardiomyopathies - prevention & control</topic><topic>Cardiomyopathy</topic><topic>Clinical medicine</topic><topic>Cybernetics</topic><topic>Disease Models, Animal</topic><topic>Ejection fraction</topic><topic>Endoplasmic reticulum</topic><topic>Heart</topic><topic>Hemodynamics</topic><topic>Homeostasis</topic><topic>Kinases</topic><topic>Laboratory animals</topic><topic>Male</topic><topic>Membrane Glycoproteins - pharmacology</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Proteins</topic><topic>Sepsis</topic><topic>Sepsis - complications</topic><topic>septic cardiomyopathy</topic><topic>Systole</topic><topic>TLR7</topic><topic>Toll-Like Receptor 7</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Saiyang, Xie</creatorcontrib><creatorcontrib>Qingqing, Wu</creatorcontrib><creatorcontrib>man, Xu</creatorcontrib><creatorcontrib>Chen, Liu</creatorcontrib><creatorcontrib>Min, Zhang</creatorcontrib><creatorcontrib>Yun, Xing</creatorcontrib><creatorcontrib>Wenke, Shi</creatorcontrib><creatorcontrib>Haiming, Wu</creatorcontrib><creatorcontrib>Xiaofeng, Zeng</creatorcontrib><creatorcontrib>Si, Chen</creatorcontrib><creatorcontrib>Haipeng, Guo</creatorcontrib><creatorcontrib>Wei, Deng</creatorcontrib><creatorcontrib>Qizhu, Tang</creatorcontrib><collection>Open Access: Wiley-Blackwell Open Access Journals</collection><collection>Wiley Free Archive</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical and translational medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Saiyang, Xie</au><au>Qingqing, Wu</au><au>man, Xu</au><au>Chen, Liu</au><au>Min, Zhang</au><au>Yun, Xing</au><au>Wenke, Shi</au><au>Haiming, Wu</au><au>Xiaofeng, Zeng</au><au>Si, Chen</au><au>Haipeng, Guo</au><au>Wei, Deng</au><au>Qizhu, Tang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Activation of Toll‐like receptor 7 provides cardioprotection in septic cardiomyopathy‐induced systolic dysfunction</atitle><jtitle>Clinical and translational medicine</jtitle><addtitle>Clin Transl Med</addtitle><date>2021-01</date><risdate>2021</risdate><volume>11</volume><issue>1</issue><spage>e266</spage><epage>n/a</epage><pages>e266-n/a</pages><issn>2001-1326</issn><eissn>2001-1326</eissn><abstract>ABSTRACT
Background
As a pattern recognition receptor, Toll‐like receptor 7 (TLR7) widely presented in the endosomal membrane of various cells. However, the precise role and mechanism of TLR7 in septic cardiomyopathy remain unknown. This study aims to determine the role of TLR7 in cardiac dysfunction during sepsis and explore the mechanism of TLR7 in septic cardiomyopathy.
Methods
We generated a mouse model of septic cardiomyopathy by challenging with lipopolysaccharide (LPS). TLR7‐knockout (TLR7−/−), wild‐type (WT) mice, cardiac‐specific TLR7‐transgenic (cTG‐TLR7) overexpression, and littermates WT (LWT) mice were subjected to septic model. Additionally, to verify the role and mechanism of TLR7 in vitro, we transfected neonatal rat ventricular myocytes (NRVMs) with Ad‐TLR7 and TLR7 siRNA before LPS administration. The effects of TLR7 were assessed by Ca2+ imaging, western blotting, immunostaining, and quantitative real‐time polymerase chain reaction (qPCR).
Results
We found that TLR7 knockout markedly exacerbated sepsis‐induced systolic dysfunction. Moreover, cardiomyocytes isolated from TLR7−/− mice displayed weaker Ca2+ handling than that in WT mice in response to LPS. Conversely, TLR7 overexpression alleviated LPS‐induced systolic dysfunction, and loxoribine (TLR7‐specific agonist) improved LPS‐induced cardiac dysfunction. Mechanistically, these optimized effects were associated with enhanced the adenosine (cAMP)‐protein kinase A (PKA) pathway, which upregulated phosphorylate‐phospholamban (p‐PLN) (Ser16) and promoted sarco/endoplasmic reticulum Ca2+ ATPase (Serca) and Ryanodine Receptor 2 (RyR2) expression in the sarcoplasmic reticulum (SR), and ultimately restored Ca2+ handling in response to sepsis. While improved Ca2+ handling was abrogated after H89 (a specific PKA inhibitor) pretreatment in cardiomyocytes isolated from cTG‐TLR7 mice. Consistently, TLR7 overexpression improved LPS‐induced Ca2+‐handling decrement in NRVMs. Nevertheless, TLR7 knockdown showed a deteriorative phenotype.
Conclusions
Our data demonstrated that activation of TLR7 protected against sepsis‐induced cardiac dysfunction through promoting cAMP‐PKA‐PLN pathway, and we revealed that TLR7 might be a novel therapeutic target to block the septic cardiomyopathy and support systolic function during sepsis.
Our study explored the effect of TLR7 activation, by which TLR7 modulated Ca2+ handling in septic cardiomyopathy. TLR7 protected against sepsis‐induced cardiac dysfunction through activation of cAMP‐PKA‐PLN pathway. Targeting this newly identified TLR7 may yield novel interventional solutions against septic cardiomyopathy.</abstract><cop>United States</cop><pub>John Wiley & Sons, Inc</pub><pmid>33463061</pmid><doi>10.1002/ctm2.266</doi><tpages>16</tpages><orcidid>https://orcid.org/0000-0003-4883-4226</orcidid><orcidid>https://orcid.org/0000-0003-2210-3169</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2001-1326 |
ispartof | Clinical and translational medicine, 2021-01, Vol.11 (1), p.e266-n/a |
issn | 2001-1326 2001-1326 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7775988 |
source | Open Access: PubMed Central; Open Access: Wiley-Blackwell Open Access Journals; Publicly Available Content (ProQuest) |
subjects | Animals Antibodies Ca2+‐handling cardiac dysfunction Cardiomyocytes Cardiomyopathies - complications Cardiomyopathies - prevention & control Cardiomyopathy Clinical medicine Cybernetics Disease Models, Animal Ejection fraction Endoplasmic reticulum Heart Hemodynamics Homeostasis Kinases Laboratory animals Male Membrane Glycoproteins - pharmacology Mice Mice, Inbred C57BL Proteins Sepsis Sepsis - complications septic cardiomyopathy Systole TLR7 Toll-Like Receptor 7 |
title | Activation of Toll‐like receptor 7 provides cardioprotection in septic cardiomyopathy‐induced systolic dysfunction |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T04%3A25%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Activation%20of%20Toll%E2%80%90like%20receptor%207%20provides%20cardioprotection%20in%20septic%20cardiomyopathy%E2%80%90induced%20systolic%20dysfunction&rft.jtitle=Clinical%20and%20translational%20medicine&rft.au=Saiyang,%20Xie&rft.date=2021-01&rft.volume=11&rft.issue=1&rft.spage=e266&rft.epage=n/a&rft.pages=e266-n/a&rft.issn=2001-1326&rft.eissn=2001-1326&rft_id=info:doi/10.1002/ctm2.266&rft_dat=%3Cproquest_pubme%3E2479042327%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4356-7580adf072c996c24ad787daa9f4910a6b10bf4de79bb857913941dc504df4f43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2762017620&rft_id=info:pmid/33463061&rfr_iscdi=true |